CGEM Cullinan Therapeutics, Inc.
Healthcare$15.46+11.71%ClosedMarket Cap: $950.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.24
P/S
0.00
EV/EBITDA
-3.31
DCF Value
$1.44
FCF Yield
-21.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-51.5%
ROA
-54.9%
ROIC
-65.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-53.7M | $-49.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-55.3M | $-50.7M | $— | — |
| FY null | $0.00 | NaN% | $-241.6M | $-219.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-55.6M | $-50.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-75.8M | $-70.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-55.0M | $-48.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-55.0M | $-47.6M | $— | — |
| FY null | $0.00 | -Infinity% | $-196.9M | $-167.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-48.9M | $-40.6M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-50.0M | $-42.0M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-43.0M | $-37.1M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-45.5M | $-23.8M | $-0.56 | — |